Is Autolus Therapeutics plc (AUTL) The Best Get Rich Fast Stocks to Buy Right Now?

Group 1 - Autolus Therapeutics plc (NASDAQ:AUTL) is currently viewed as a consensus buy among eleven analysts, with a median price target of $10, indicating an upside potential of 495.24% [1] - Analyst Yanan Zhu from Wells Fargo reaffirmed a 'Buy' rating for Autolus, setting a price target of $5, which represents an upside potential of approximately 198% [1] - The company recently presented preliminary data from its Phase 1 CARLYSLE trial, showing positive responses in patients with refractory systemic lupus erythematosus (srSLE) treated with CAR-T cell therapy obecabtagene autoleucel (obe-cel) [2] Group 2 - In the CARLYSLE trial, three patients achieved a complete response, while five patients met DORIS response criteria, with a median onset of 5.1 months [3] - Nine patients were assessable for safety across both the 50 million and 100 million cell dose cohorts, indicating a thorough evaluation of the treatment's safety profile [3] - Autolus Therapeutics is focused on developing next-generation T-cell immunotherapies for cancer and autoimmune diseases, highlighting its commitment to innovative biopharmaceutical solutions [3]